{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T19:18:55Z","timestamp":1791227935826,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.msard.2019.101512","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T20:42:53Z","timestamp":1573245773000},"page":"101512","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3886-2813","authenticated-orcid":false,"given":"Ertugrul Cagri","family":"Bolek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Sari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Levent","family":"Kilic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asli","family":"Kurne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kader K.","family":"Oguz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Akif","family":"Topcuoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ihsan","family":"Ertenli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Karadag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4 Suppl 50","key":"10.1016\/j.msard.2019.101512_bib0001","first-page":"S84","article-title":"Cyclosporine for Behcet\u2019s\u00a0 uveitis: is it associated with an increased risk of neurological involvement?","volume":"26","author":"Akman-Demir","year":"2008","journal-title":"Clin. Exp. Rheumatol."},{"issue":"Pt 11","key":"10.1016\/j.msard.2019.101512_bib0002","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/brain\/122.11.2171","article-title":"Clinical patterns of neurological involvement in Behcet's disease: evaluation of 200 patients. The Neuro-Behcet Study Group","volume":"122","author":"Akman-Demir","year":"1999","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2019.101512_bib0003","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S1474-4422(09)70015-8","article-title":"Neuro- Behcet\u2019s disease: epidemiology, clinical characteristics, and management","volume":"8","author":"Al-Araji","year":"2009","journal-title":"Lancet Neurol."},{"issue":"3","key":"10.1016\/j.msard.2019.101512_bib0004","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1161\/01.STR.0000258355.23810.c6","article-title":"Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis","volume":"38","author":"Banks","year":"2007","journal-title":"Stroke"},{"issue":"6 Suppl 102","key":"10.1016\/j.msard.2019.101512_bib0005","first-page":"82","article-title":"The association between the parenchymal neurological involvement and posterior uveitis in Behcet\u2019s syndrome","volume":"34","author":"Bitik","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.msard.2019.101512_bib0006","article-title":"Interferon alpha might be an alternative therapeutic choice for refractory neuro-Behcet\u2019s disease","volume":"29","author":"Bolek","year":"2019","journal-title":"Mult. Scler. Rel. Disord."},{"issue":"5","key":"10.1016\/j.msard.2019.101512_bib0007","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1136\/ard.62.5.492","article-title":"Effects of interferon alpha treatment on the clinical course of refractory Behcet\u2019s disease: an open study","volume":"62","author":"Calguneri","year":"2003","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.msard.2019.101512_bib0008","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1756-185X.2010.01549.x","article-title":"Behcet\u2019s disease in Iran: analysis of 6500 cases","volume":"13","author":"Davatchi","year":"2010","journal-title":"Int. J. Rheum. Dis."},{"issue":"23","key":"10.1016\/j.msard.2019.101512_bib0009","doi-asserted-by":"crossref","first-page":"e3550","DOI":"10.1097\/MD.0000000000003550","article-title":"Efficacy of anti-TNFalpha in severe and refractory neuro-Behcet disease: an observational study","volume":"95","author":"Desbois","year":"2016","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.msard.2019.101512_bib0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/cei.13049","article-title":"Is Behcet\u2019s disease a \u2018class 1-opathy\u2019? The role of HLA-B*51 in the pathogenesis of Behcet\u2019s disease","volume":"191","author":"Giza","year":"2018","journal-title":"Clin. Exp. Immunol."},{"issue":"6","key":"10.1016\/j.msard.2019.101512_bib0011","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Behcet\u2019s syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann. Rheum. Dis."},{"issue":"3","key":"10.1016\/j.msard.2019.101512_bib0012","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/s10165-011-0533-5","article-title":"Clinical characteristics of neuro-Behcet\u2019s disease in Japan: a multicenter retrospective analysis","volume":"22","author":"Hirohata","year":"2012","journal-title":"Mod. Rheumatol."},{"issue":"6","key":"10.1016\/j.msard.2019.101512_bib0013","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1007\/s00415-010-5454-2","article-title":"Neurological manifestations of Behcet\u2019s disease in Japan: a study of 54 patients","volume":"257","author":"Ideguchi","year":"2010","journal-title":"J. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2019.101512_bib0014","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/jdv.12107","article-title":"The international criteria for Behcet's disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria","volume":"28","year":"2014","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"8697","key":"10.1016\/j.msard.2019.101512_bib0015","first-page":"1078","article-title":"Criteria for diagnosis of Behcet\u2019s disease","volume":"335","year":"1990","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.msard.2019.101512_bib0016","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s00415-013-7209-3","article-title":"Diagnosis and management of neuro-Behcet\u2019s disease: international consensus recommendations","volume":"261","author":"Kalra","year":"2014","journal-title":"J. Neurol."},{"issue":"Suppl 2","key":"10.1016\/j.msard.2019.101512_bib0017","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/annrheumdis-2017-eular.5322","article-title":"FRI0342\u2005Distribution of vasculitides in eastern mediterranean: results of a prospective cohort","volume":"76","author":"Karadag","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"10","key":"10.1016\/j.msard.2019.101512_bib0018","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1007\/s00415-017-8436-9","article-title":"Neurological complications of Behcet\u2019s syndrome","volume":"264","author":"Kidd","year":"2017","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.msard.2019.101512_bib0019","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","article-title":"The use of interferon alpha in Behcet disease: review of the literature","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"issue":"5","key":"10.1016\/j.msard.2019.101512_bib0020","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.semarthrit.2003.09.005","article-title":"Differential efficacy of human recombinant interferon-alpha2a on ocular and extraocular manifestations of Behcet disease: results of an open 4-center trial","volume":"33","author":"Kotter","year":"2004","journal-title":"Semin. Arthritis Rheum."},{"issue":"1","key":"10.1016\/j.msard.2019.101512_bib0021","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005792-200301000-00006","article-title":"The long-term mortality and morbidity of Behcet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center","volume":"82","author":"Kural-Seyahi","year":"2003","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.msard.2019.101512_bib0022","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/crad.2000.0675","article-title":"MRI findings in neuro-Behcet\u2019s disease","volume":"56","author":"Lee","year":"2001","journal-title":"Clin. Radiol."},{"key":"10.1016\/j.msard.2019.101512_bib0023","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.msard.2018.10.117","article-title":"Which treatment strategies for polyrefractory neuro-Behcet disease?","volume":"27","author":"London","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"5","key":"10.1016\/j.msard.2019.101512_bib0024","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/rheumatology\/ker428","article-title":"Relationships of HLA-B51 or B5 genotype with Behcet\u2019s disease clinical characteristics: systematic review and meta-analyses of observational studies","volume":"51","author":"Maldini","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.msard.2019.101512_bib0025","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1399-0039.1981.tb00687.x","article-title":"Behcet\u2019s disease: lack of correlation of clinical manifestations with HLA antigens","volume":"17","author":"Muftuoglu","year":"1981","journal-title":"Tissue Antigens"},{"issue":"2","key":"10.1016\/j.msard.2019.101512_bib0026","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/00041327-200106000-00011","article-title":"Interferon-alpha 2a treatment of neuro-Behcet disease","volume":"21","author":"Nichols","year":"2001","journal-title":"J. Neuroophthalmol."},{"issue":"5","key":"10.1016\/j.msard.2019.101512_bib0027","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/art.38351","article-title":"Long-term outcome of neuro-Behcet's disease","volume":"66","author":"Noel","year":"2014","journal-title":"Arthritis Rheumatol."},{"issue":"5","key":"10.1016\/j.msard.2019.101512_bib0028","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.3904\/kjim.2016.202","article-title":"Clinical phenotypes of Korean patients with Behcet disease according to gender, age at onset, and HLA-B51","volume":"33","author":"Ryu","year":"2018","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.msard.2019.101512_bib0029","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1016\/B978-0-7020-4088-7.00110-3","article-title":"Neuro-Behcet syndrome","volume":"121","author":"Saip","year":"2014","journal-title":"Handb. Clin. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2019.101512_bib0030","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/archneur.1989.00520390031011","article-title":"Neurologic involvement in Behcet\u2019s syndrome: a prospective study.","volume":"46","author":"Serdaroglu","year":"1989","journal-title":"Arch. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2019.101512_bib0031","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s00415-009-0145-6","article-title":"The spectrum of nervous system involvement in Behcet\u2019s syndrome and its differential diagnosis","volume":"256","author":"Siva","year":"2009","journal-title":"J. Neurol."},{"issue":"3 Suppl 72","key":"10.1016\/j.msard.2019.101512_bib0032","first-page":"S69","article-title":"Behcet's disease: features of neurological involvement in a dedicated centre in Italy","volume":"30","author":"Talarico","year":"2012","journal-title":"Clin. Exp. Rheumatol."},{"issue":"9","key":"10.1016\/j.msard.2019.101512_bib0033","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1161\/01.STR.0000177872.87960.61","article-title":"Optimizing cutoff scores for the Barthel index and the modified Rankin scale for defining outcome in acute stroke trials","volume":"36","author":"Uyttenboogaart","year":"2005","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.msard.2019.101512_bib0034","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1034\/j.1399-0039.1999.540301.x","article-title":"Behcet\u2019s disease, the silk road and HLA-B51: historical and geographical perspectives","volume":"54","author":"Verity","year":"1999","journal-title":"Tissue Antigens"},{"issue":"3","key":"10.1016\/j.msard.2019.101512_bib0435","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s11926-003-0066-9","article-title":"Beh\u00e7et's syndrome: an update","volume":"5","author":"Yazici","year":"2003","journal-title":"Curr. Rheumatol. Rep."},{"issue":"3","key":"10.1016\/j.msard.2019.101512_bib0035","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ncprheum0436","article-title":"Behcet's syndrome: disease manifestations, management, and advances in treatment","volume":"3","author":"Yazici","year":"2007","journal-title":"Nat. Clin. Pract. Rheumatol."},{"issue":"7","key":"10.1016\/j.msard.2019.101512_bib0036","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1111\/j.1468-1331.2007.01754.x","article-title":"Clinical characteristics and course of spinal cord involvement in Behcet\u2019s disease","volume":"14","author":"Yesilot","year":"2007","journal-title":"Eur. J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819305012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034819305012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:46:47Z","timestamp":1761900407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034819305012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":37,"alternative-id":["S2211034819305012"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.101512","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features and disease course of neurological involvement in Behcet's disease: HUVAC experience","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.101512","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101512"}}